Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Gastrointestinal 1

Conditions

Cholangiocarcinoma 2Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Bevacizumab 6Nivolumab 5pembrolizumab 4Gemcitabine 4Cisplatin 3regorafenib 2fludarabine 2Sorafenib 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1spartalizumab 1sonidegib 1selinexor 1sargramostim 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1pazopanib 1olutasidenib 1olaparib 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × olutasidenib × Gastrointestinal × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡